Ito K, Nakagawa M, Shimokawa M, Hori K, et al. Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601. Anticancer Drugs 2023;34:857-865.
PMID: 36729915